monoclon
antibodi
mab
produc
b
cell
specif
target
antigen
hybridoma
techniqu
introduc
milstein
made
possibl
obtain
pure
mab
larg
amount
greatli
enhanc
basic
research
potenti
clinic
use
scientif
technolog
advanc
also
enabl
success
translat
mab
clinic
around
world
least
therapeut
mab
studi
clinic
trial
commerci
compani
therapeut
mab
approv
unit
state
food
drug
administr
us
fda
current
market
includ
mab
treatment
cancer
tabl
increas
import
therapeut
mab
appar
fig
mab
becom
predomin
treatment
modal
variou
diseas
past
year
time
major
technolog
advanc
made
discoveri
develop
mab
therapi
quicker
effici
sinc
new
mab
approv
contribut
total
global
market
mab
clinic
use
end
accord
us
fda
strikingli
total
new
antibodi
grant
approv
us
fda
number
talli
inform
contain
variou
websit
includ
antibodi
societi
databas
therapeut
antibodi
compani
pipelin
press
releas
list
antibodybas
drug
approv
us
fda
shown
tabl
first
therapeut
mab
orthoclon
approv
us
fda
compris
murin
mab
cellexpress
function
immunosuppress
treatment
acut
transplant
reject
market
end
date
juli
tabl
overcom
problem
decreas
immunogen
potenti
efficaci
make
possibl
therapeut
use
antibodi
extend
durat
research
develop
techniqu
transform
rodent
antibodi
structur
similar
human
antibodi
without
loss
bind
properti
first
chimer
antibodi
antigpiibiiia
antigenbind
fragment
fab
abciximab
approv
us
fda
inhibit
platelet
aggreg
cardiovascular
diseas
fig
drug
develop
combin
sequenc
murin
variabl
domain
human
constant
region
domain
fig
first
mab
oncolog
indic
rituximab
chimer
approv
nonhodgkin
lymphoma
us
fda
fig
one
except
advanc
acceler
approv
therapeut
mab
gener
human
antibodi
complementarydetermin
region
cdr
graft
techniqu
cdr
graft
nonhuman
antibodi
cdr
sequenc
transplant
human
framework
sequenc
order
maintain
target
specif
fig
first
human
mab
approv
us
fda
receptor
daclizumab
prevent
transplant
reject
fig
human
antibodi
made
possibl
clinic
appli
new
class
biolog
direct
diseas
requir
longterm
treatment
cancer
autoimmun
diseas
base
success
human
mab
clinic
key
discoveri
technolog
obtain
fulli
human
mab
fig
develop
sir
gregori
p
winter
techniqu
base
phage
display
wherein
divers
exogen
gene
incorpor
filament
bacteriophag
compos
librari
librari
protein
present
phage
surfac
fusion
phage
coat
protein
allow
select
specif
binder
affin
characterist
phage
display
techniqu
first
introduc
georg
p
smith
compris
power
method
rapid
identif
peptid
antibodi
fragment
singl
chain
fragment
variabl
scfv
fab
bind
varieti
target
molecul
protein
cellsurfac
glycan
receptor
fig
nobel
prize
chemistri
award
georg
p
smith
sir
gregori
p
winter
georg
smith
develop
phagedisplay
peptid
use
evolv
new
protein
gregori
p
winter
abl
appli
phagedisplay
antibodi
librari
discoveri
isol
antibodi
phage
display
technolog
also
use
antibodi
matur
sitedirect
mutagenesi
cdr
affin
select
base
techniqu
first
fulli
human
therapeut
antibodi
adalimumab
humira
antitumor
necrosi
factor
human
antibodi
approv
us
fda
rheumatoid
arthriti
fig
nine
human
antibodi
drug
gener
phage
display
approv
us
fda
tabl
transgen
anim
repres
anoth
technolog
obtain
fulli
human
mab
fig
technolog
introduc
public
two
transgen
mous
line
humabmous
xenomous
line
genet
modifi
human
immunoglobulin
ig
gene
insert
genom
replac
endogen
ig
gene
make
anim
capabl
synthes
fulli
human
antibodi
upon
immun
first
human
antibodi
gener
transgen
mous
antiepiderm
growth
factor
receptor
egfr
panitumumab
approv
us
fda
fig
number
fulli
human
antibodi
made
transgen
mice
increas
rapidli
number
approv
drug
current
tabl
depend
immun
protocol
highaffin
human
antibodi
obtain
select
hybridoma
clone
gener
immun
transgen
mice
use
theoret
similar
approach
gener
neutral
human
antibodi
human
b
cell
also
yield
promis
result
infecti
diseas
therapeut
recent
develop
bispecif
antibodi
offer
attract
new
opportun
design
novel
protein
therapeut
bispecif
antibodi
gener
util
protein
engin
techniqu
link
two
antigen
bind
domain
fab
scfv
allow
singl
antibodi
simultan
bind
differ
antigen
thu
bispecif
antibodi
may
engin
exhibit
novel
function
exist
mixtur
two
parent
antibodi
bispecif
antibodi
design
recruit
cytotox
effector
cell
immun
system
target
pathogen
cell
first
approv
bispecif
antibodi
catumaxomab
europ
catumaxomab
target
epcam
treat
solid
tumor
patient
malign
ascit
howev
drug
withdrawn
market
commerci
reason
current
two
bispecif
antibodi
obtain
us
fda
approv
market
first
blinatumomab
bispecif
tcell
engag
bite
target
treatment
bcell
precursor
acut
lymphoblast
leukemia
second
emicizumab
fullsiz
bispecif
igg
natur
architectur
bind
activ
coagul
factor
ix
x
treatment
haemophilia
date
bispecif
antibodi
clinic
trial
evalu
cancer
therapi
concept
platform
drive
develop
bispecif
antibodi
continu
advanc
rapidli
creat
mani
new
opportun
make
major
therapeut
breakthrough
mab
routin
use
biochemistri
molecular
cellular
biolog
medic
research
perhap
benefici
applic
use
therapeut
drug
treatment
human
diseas
cancer
asthma
arthriti
psoriasi
crohn
diseas
transplant
reject
migrain
headach
infecti
diseas
tabl
import
advanc
antibodi
engin
made
past
decad
enhanc
safeti
efficaci
therapeut
antibodi
develop
along
greater
understand
immunomodulatori
properti
antibodi
pave
way
next
gener
new
improv
antibodybas
drug
treatment
human
diseas
mab
market
enjoy
healthi
pipelin
expect
grow
increas
pace
current
valuat
billion
despit
high
growth
potenti
new
compani
unlik
take
larg
share
market
current
domin
seven
compani
genentech
abbvi
johnson
johnson
bristolmy
squibb
merck
sharp
dohm
novarti
amgen
compani
compris
remain
mani
mab
product
achiev
annual
sale
us
billion
fig
six
adalimumab
nivolumab
pembrolizumab
trastuzumab
bevacizumab
rituximab
sale
billion
tabl
adalimumab
humira
highest
sale
figur
ever
record
biopharmaceut
product
nearli
billion
top
ten
sell
mab
product
list
tabl
topsel
mab
drug
rank
base
sale
revenu
report
biolog
pharmacolog
compani
press
announc
confer
call
annual
report
investor
materi
throughout
drug
name
sponsor
diseas
indic
sale
shown
mab
increasingli
use
broad
rang
target
oncolog
immunolog
hematolog
remain
preval
medic
applic
mab
multipl
diseas
indic
least
one
cancerrel
lymphoma
myeloma
melanoma
glioblastoma
neuroblastoma
sarcoma
colorect
lung
breast
ovarian
head
neck
cancer
oncolog
diseas
medic
specialti
access
mab
treatment
moreov
number
target
protein
known
function
either
stimulatori
inhibitori
checkpoint
immun
system
dramat
expand
numer
antibodi
therapeut
target
program
cell
death
protein
cemiplimab
nivolumab
pembrolizumab
ligand
program
deathligand
durvalumab
avelumab
atezolizumab
cytotox
antigen
ipilimumab
grant
market
approv
adalimumab
humira
world
bestsel
drug
adalimumab
subcutan
administ
biolog
diseas
modifi
use
treatment
rheumatoid
arthriti
chronic
debilit
diseas
origin
launch
abbvi
unit
state
gain
approv
us
fda
shown
adalimumab
reduc
sign
symptom
moder
sever
rheumatoid
arthriti
adult
also
use
treat
psoriat
arthriti
ankylos
spondyl
crohn
diseas
ulcer
coliti
psoriasi
hidraden
suppurativa
uveiti
juvenil
idiopath
arthriti
may
use
alon
combin
diseasemodifi
antirheumat
drug
immun
checkpoint
import
maintain
selftoler
temper
physiolog
immun
respons
peripher
tissu
therefor
molecul
underli
checkpoint
recent
drawn
consider
interest
cancer
immunotherapi
nivolumab
opdivo
pembrolizumab
keytruda
mab
second
third
bestsel
mab
drug
tabl
nivolumab
human
antibodi
block
signal
normal
prevent
activ
cell
attack
cancer
cell
target
nivolumab
receptor
antibodi
block
interact
ligand
releas
pathwaymedi
immun
inhibit
pembrolizumab
human
antibodi
use
cancer
immunotherapi
treat
melanoma
lung
cancer
head
neck
cancer
hodgkin
lymphoma
stomach
cancer
pembrolizumab
firstlin
treatment
nsclc
cancer
cell
overexpress
mutat
egfr
anaplast
lymphoma
kinas
larg
random
clinic
trial
indic
nsclc
patient
treat
nivolumab
pembrolizumab
approv
us
fda
show
increas
overal
surviv
compar
docetaxel
standard
secondlin
treatment
total
new
mab
approv
us
major
product
approv
noncanc
indic
perhap
reflect
higher
approv
success
rate
antibodi
treatment
diseas
three
antibodi
erenumab
galcanezumab
fremaezumab
approv
migrain
prevent
one
ibalizumab
use
human
immunodefici
viru
hiv
infect
three
migraineprev
drug
erenumab
aimovig
galcanezumab
emgal
fremaezumab
ajovi
mab
block
activ
calcitonin
generel
peptid
cgrp
receptor
migrain
etiolog
cgrp
act
heteromer
receptor
compos
g
proteincoupl
receptor
calcitonin
receptorlik
receptor
calcrl
receptor
activitymodifi
protein
galcanezumab
fremaezumab
bind
cgrp
block
bind
receptor
howev
erenumab
one
three
antibodi
target
extracellular
domain
human
g
proteincoupl
receptor
calcrl
interf
cgrp
bind
pocket
mani
mab
develop
treatment
infecti
diseas
current
four
approv
us
fda
raxibacumab
obiltoxaximab
treatment
inhal
anthrax
palivizumab
prevent
respiratori
syncyti
viru
highrisk
infant
ibalizumab
treatment
hiv
infect
patient
ibalizumab
trogarzo
human
mab
use
domain
postattach
inhibitor
us
fda
approv
ibalizumab
adult
patient
infect
hiv
previous
treat
resist
current
avail
therapi
compani
current
sponsor
clinic
studi
mab
approxim
earlystag
studi
design
assess
safeti
phase
safeti
preliminari
efficaci
phase
iii
phase
ii
patient
popul
mab
phase
cancer
treatment
proport
mab
intend
treat
cancer
similar
current
phase
ii
latestag
clinic
studi
pivot
phase
ii
phase
iiiii
phase
iii
twentynin
novel
antibodi
therapeut
latestag
clinic
studi
noncanc
indic
among
trial
mab
singl
therapeut
area
predomin
immunemedi
disord
compris
largest
group
group
potenti
treatment
leronlimab
brolucizumab
enter
regulatori
review
end
five
mab
eptinezumab
teprotumumab
crizanlizumab
satralizumab
tanezumab
may
enter
regulatori
review
comparison
novel
antibodi
therapeut
latestag
clinic
studi
cancer
indic
antibodi
therapeut
solid
tumor
clearli
predomin
less
candid
intend
sole
hematolog
malign
five
mab
isatuximab
spartalizumab
tafasitamab
dostarlimab
ublituximab
licens
applic
submit
us
fda
isatuximab
chimer
mab
evalu
treatment
patient
multipl
myeloma
mm
combin
isatuximab
differ
chemotherapi
test
three
phase
iii
studi
icaria
ikema
imroz
mm
patient
icaria
studi
evalu
effect
isatuximab
combin
pomalidomid
dexamethason
compar
chemotherapi
patient
refractori
relaps
mm
pivot
phase
iii
icariamm
trial
result
demonstr
isatuximab
combin
therapi
show
statist
signific
improv
compar
pomalidomid
dexamethason
alon
patient
relaps
refractori
mm
us
fda
accept
review
biolog
licens
applic
isatuximab
treatment
relaps
refractori
mm
patient
target
action
date
fda
decis
april
ikema
imroz
studi
evalu
isatuximab
chemotherapeaut
combin
mm
patient
spartalizumab
human
mab
bind
subnanomolar
affin
block
interact
prevent
inhibitori
signal
lead
tcell
activ
clinic
studi
spartalizumab
underway
random
doubleblind
placebocontrol
phase
iii
combii
studi
evalu
safeti
efficaci
dabrafenib
trametinib
combin
spartalizumab
compar
match
placebo
previous
untreat
patient
braf
unresect
metastat
melanoma
primari
endpoint
studi
assess
doselimit
toxic
chang
level
cell
tumor
microenviron
progressionfre
surviv
key
secondari
endpoint
overal
surviv
overal
respons
rate
durat
respons
estim
primari
complet
date
studi
septemb
dostarlimab
mab
may
use
treatment
sever
type
cancer
glaxosmithklin
announc
result
phase
dose
escal
cohort
expans
studi
garnet
expect
support
biolog
licens
applic
submiss
us
fda
dostarlimab
assess
patient
advanc
solid
tumor
limit
avail
treatment
option
garnet
studi
drug
administ
dose
mg
everi
week
first
cycl
mg
everi
week
thereaft
four
patient
cohort
microsatellit
instabl
high
msih
endometri
cancer
msih
nonendometri
cancer
microsatellitest
endometri
cancer
nonsmal
cell
lung
cancer
dostarlimab
also
evalu
anoth
phase
iii
studi
compar
platinumbas
therapi
dostarlimab
niraparib
versu
standard
care
platinumbas
therapi
firstlin
treatment
stage
iii
iv
nonmucin
epitheli
ovarian
cancer
ublituximab
glycoengin
antibodi
current
clinic
investig
five
latestag
clinic
studi
differ
cancer
chronic
lymphocyt
leukemia
cll
nonhodgkin
lymphoma
noncanc
multipl
sclerosi
indic
three
phase
iii
studi
explor
efficaci
ublituximab
combin
anticanc
agent
among
studi
unitycl
phase
iii
studi
evalu
combin
ublituximab
delta
inhibitor
compar
obinutuzumab
plu
chlorambucil
untreat
previous
treat
cll
patient
two
phase
iii
studi
ultim
ultim
evalu
efficaci
safeti
ublituximab
compar
teriflunomid
patient
relaps
multipl
sclerosi
human
mab
cdr
light
heavi
chain
murin
enter
clinic
develop
first
time
cdr
graft
one
popular
techniqu
product
human
mab
origin
develop
gregori
p
winter
use
technolog
nonhuman
cdr
sequenc
transplant
human
framework
sequenc
allow
antibodi
maintain
bind
activ
target
antigen
first
us
fda
approv
cdrgraft
human
mab
occur
daclizumab
bind
receptor
use
prevent
transplant
reject
queen
collabor
develop
daclizumab
use
cdr
graft
also
use
human
framework
maxim
homolog
murin
framework
order
decreas
loss
antigen
recognit
case
certain
amino
acid
murin
framework
crucial
maintain
antibodi
bind
activ
residu
may
cooper
cdr
present
antibodi
paratop
directli
interact
antigen
current
crucial
framework
residu
identifi
observ
structur
antibodyantigen
complex
xray
crystallographi
cryoelectron
microscopi
computeraid
protein
homolog
model
posit
amino
acid
framework
may
consid
restor
human
back
mous
mutat
cdrgraft
human
antibodi
therebi
improv
affin
stabil
final
product
current
web
server
develop
integr
bioinformat
antibodi
structur
databas
render
human
experi
provid
tool
human
templat
select
graft
backmut
evalu
antibodi
model
howev
bind
activ
antibodi
still
compromis
perform
affin
matur
improv
situat
multipl
method
develop
quantifi
human
variabl
region
mab
abhinandan
martin
design
tool
call
hscore
assess
degre
human
antibodi
sequenc
calcul
mean
sequenc
ident
compar
subset
human
variabl
region
sequenc
databas
germin
index
defin
subsequ
assist
germlin
human
macaqu
antibodi
gscore
deriv
hscore
improv
classif
germlin
framework
sequenc
score
analyz
establish
larg
databas
human
antibodi
variabl
region
sequenc
clearli
separ
human
sequenc
mous
sequenc
mani
speci
well
use
reveal
similar
human
antibodi
fulli
human
antibodi
human
score
tool
avail
onlin
allow
assist
gener
human
antibodi
use
human
antibodi
help
greatli
improv
clinic
toler
mab
therapeut
intric
control
antibodi
sequenc
open
door
engin
mab
wide
rang
possibl
applic
medicin
current
half
mab
use
treat
human
chimer
human
fig
tabl
one
wellknown
human
antibodi
trastuzumab
herceptin
approv
achiev
annual
sale
billion
tabl
trastuzumab
use
treatment
patient
human
epiderm
growth
factor
receptor
posit
metastat
breast
cancer
gastroesophag
junction
adenocarcinoma
use
mab
clinic
set
sever
essenti
biophys
properti
includ
high
antigen
bind
activ
high
stabil
low
immunogen
antibodi
immunogen
mean
degre
host
immun
system
recogn
react
therapeut
agent
antidrug
antibodi
ada
induc
immun
system
found
immunogen
occur
patient
administ
antibodi
drug
antidrug
antibodi
potenti
neutral
therapeut
agent
reduc
efficaci
drug
importantli
antidrug
antibodi
may
caus
advers
effect
rang
skin
rash
system
inflammatori
respons
patient
impact
safeti
efficaci
antibodi
drug
clinic
use
immunogen
influenc
sever
factor
drug
dosag
administr
strategi
rout
combin
impur
contamin
aggreg
aris
abag
bind
complex
structur
featur
sequenc
variat
glycosyl
human
antibodi
harbor
human
sequenc
constant
region
nearli
human
sequenc
fv
cdr
murin
graft
antibodi
humanlik
usual
allow
higher
toler
lower
immunogen
clinic
set
exampl
perpetua
et
al
show
case
support
concept
compar
human
antibodi
parent
murin
version
demonstr
human
offer
signific
reduct
immunogen
howev
human
antibodi
retain
murin
cdr
could
regard
foreign
antigen
host
immun
system
eventu
aris
immunogen
exampl
ada
detect
women
metastat
breast
cancer
treat
trastuzumab
therapeut
cours
recent
immunogen
analysi
result
clinic
data
show
ada
rate
posit
breast
cancer
patient
treatment
trastuzumab
variat
immunogen
antibodi
drug
may
caus
mani
potenti
factor
age
race
genet
background
relat
diseas
program
drug
administr
cdr
framework
fulli
human
antibodi
deriv
human
immunoglobulin
gene
repertoir
thu
theoret
bypass
immunogen
howev
sever
fulli
human
antibodi
report
induc
mark
immun
respons
administr
patient
adalimumab
humira
human
report
gener
signific
immun
respons
elicit
antiidiotyp
antibodi
part
patient
vari
depend
diseas
therapi
golimumab
simponi
fulli
human
antibodi
combin
methotrex
treatment
rheumatoid
arthriti
caus
patient
produc
antidrug
antibodi
one
reason
scenario
fv
sequenc
human
antibodi
ident
human
germlin
antibodi
evolut
vj
vdj
random
recombin
well
affin
matur
natur
occur
vivo
somat
hypermut
vitro
insilico
assay
precis
analyz
immunogen
antibodi
vivo
assess
usual
use
evalu
immunogen
result
amelior
design
engin
antibodi
therapeut
reduc
potenti
induc
antidrug
antibodi
phage
display
first
still
wide
use
technolog
vitro
antibodi
select
strategi
develop
base
excel
work
georg
p
smith
use
recombin
dna
techniqu
fuse
foreign
peptid
coat
protein
piii
bacteriophag
order
display
peptid
bacteriophag
surfac
creat
antibodyselect
phage
vector
describ
vitro
method
enabl
affin
select
antigenspecif
phagedisplay
antibodi
excess
phage
pool
later
discov
scfv
small
antibodi
format
express
phage
filament
time
three
differ
research
institut
independ
establish
phagedisplay
scfv
fab
antibodi
librari
mrc
laboratori
molecular
biolog
uk
german
cancer
research
center
germani
scripp
research
institut
usa
sinc
phagedisplay
antibodi
librari
proven
reliabl
discoveri
platform
identif
potent
fulli
human
mab
process
identifi
mab
phagedisplay
librari
begin
antibodylibrari
construct
fig
variabl
heavi
vh
variabl
light
vl
polymeras
chain
reaction
pcr
product
repres
ig
geneencod
repertoir
ligat
phage
display
vector
phagemid
high
qualiti
mrna
human
peripher
blood
mononuclear
cell
pbmc
reversetranscrib
cdna
differ
vh
vl
chainregion
gene
famili
amplifi
use
specif
primer
amplifi
transcrib
variabl
region
within
ig
repertoir
format
antibodi
phagedisplay
librari
either
scfv
fab
fragment
fig
scfv
compos
vh
vl
domain
connect
short
flexibl
linker
antibodi
fab
fragment
display
phage
coat
protein
compar
higher
structur
stabil
readili
convert
intact
igg
antibodi
usual
without
impair
bind
activ
eleg
phagedisplay
librari
appar
linkag
antibodi
phenotyp
specif
sensit
genotyp
genet
inform
via
phage
particl
due
small
size
high
solubl
particlesml
phage
particl
repertoir
size
independ
clone
effici
produc
display
singl
librari
gene
repertoir
phage
display
librari
obtain
immun
anim
librari
may
synthet
construct
use
random
cdr
sequenc
within
fix
framework
phage
display
antibodi
librari
construct
rearrang
v
gene
igm
repertoir
gene
sequenc
deriv
b
cell
human
donor
librari
rel
close
human
antibodi
germ
line
low
risk
immunogen
main
advantag
immun
librari
librari
antibodi
gene
immun
librari
undergon
natur
affin
matur
vivo
allow
develop
highaffin
antibodi
target
howev
approach
requir
immunogen
respons
success
induc
antigen
interest
new
librari
must
prepar
new
target
singl
larg
synthet
librari
yield
high
affin
antibodi
subnanomolar
rang
wide
spectrum
target
therefor
nonimmun
librari
distinct
advantag
avoid
issu
immunolog
toler
immun
mice
requir
new
immun
librari
new
target
current
almost
wide
access
commerci
librari
base
highli
divers
nonimmun
gene
repertoir
allow
select
antibodi
virtual
unlimit
number
target
worth
note
antibodi
drug
undergon
evalu
clinic
trial
origin
companyown
librari
librari
includ
cambridg
antibodi
technolog
medimmun
subsidiari
astrazeneca
scfvfragment
librari
dyax
corp
shire
human
fabfrag
librari
scfv
fab
librari
xoma
fulli
synthet
human
combinatori
antibodi
scfv
hucal
fab
hucalgold
librari
develop
morphosi
antibodi
librari
typic
screen
iter
select
cycl
enrich
targetbind
phage
follow
amplif
bound
phage
e
coli
cell
affin
screen
process
antibodi
librari
call
biopan
fig
repeat
round
select
allow
enrich
rare
antigenbind
phage
clone
eventu
result
select
highli
specif
binder
stringent
process
critic
featur
phage
display
allow
mab
isol
period
short
coupl
week
far
quickli
tradit
hybridoma
method
vitro
select
necessari
immobil
target
antigen
solid
surfac
polystyren
surfac
high
protein
bind
capac
immunopl
immunotub
wide
use
antigen
immobil
addit
magnet
bead
protein
ga
streptavidin
maleimid
nhydroxysuccinimid
use
immobil
antigen
perform
biopan
solut
biopan
method
restrict
known
recombin
protein
fact
phage
display
techniqu
may
also
util
select
antibodi
whole
cell
unveil
previous
unknown
antigen
tumor
cell
surfac
cancer
extrem
heterogen
diseas
tumor
cell
stemlik
properti
abl
initi
sustain
tumor
develop
cell
often
refer
tumor
initi
cell
cancer
stem
cell
csc
phage
display
technolog
well
suit
applic
csc
research
sever
antibodi
alreadi
identifi
phage
display
librari
abil
bind
known
csc
marker
moreov
novel
csc
surfac
marker
may
identifi
select
phagedisplay
antibodi
bind
csclike
popul
identifi
correspond
target
antigen
use
tumor
biopsi
tissu
biolog
materi
allow
research
probe
tumor
microenviron
may
highli
relev
clinic
use
phage
display
technolog
use
probe
cancer
tissu
biopsi
order
gener
antibodi
fragment
specif
recogn
tumor
subpopul
csc
tumorassoci
endotheli
cell
well
clinic
relev
tumor
antigen
antibodi
antibodi
fragment
refer
target
drug
deliveri
missil
abil
direct
home
drug
tumor
exampl
immunoliposom
demonstr
provid
convent
liposom
drug
cancer
target
abil
increas
therapeut
efficaci
anticanc
drug
cellular
intern
target
ligand
essenti
outcom
success
tumortarget
liposom
drug
deliveri
reason
effici
phage
displaybas
select
approach
design
map
tumor
intern
epitop
wherein
phagedisplay
librari
incub
live
cancer
cell
method
success
appli
rapidli
identifi
sever
scfv
high
rate
intern
sever
type
tumor
target
antigen
subsequ
identifi
intracellular
drug
deliveri
system
develop
identif
mab
phage
display
entir
vitro
process
thu
restrict
immunolog
toler
allow
identif
antibodi
poorli
immunogen
antigen
difficult
obtain
use
anim
immun
method
eg
glycan
toxic
agent
vitro
natur
assay
especi
use
identifi
specif
antibodi
novel
genemut
pathogen
outbreak
emerg
infecti
diseas
antigen
pathogen
usual
induc
strong
immun
respons
patient
make
common
infect
individu
natur
produc
highaffin
antibodi
obtain
antibodi
mrna
pbmc
pathogeninfect
peopl
quickli
collect
use
gene
repertoir
phagedisplay
librari
librari
allow
rapid
identif
highaffin
antibodi
may
use
guid
vaccin
design
develop
therapeut
drug
diagnost
reagent
moreov
biopan
approach
modifi
isol
identifi
antibodi
broad
neutral
activ
pandem
influenza
viru
chen
et
al
report
establish
phagedisplay
fab
librari
deriv
pbmc
convalesc
patient
infect
novel
influenza
viru
broke
use
librari
antibodi
target
purifi
virion
isol
two
human
antibodi
found
exhibit
high
neutral
activ
live
viru
due
interact
receptorbind
site
viral
hemagglutinin
antigen
newli
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
induc
sever
acut
respiratori
syndromelik
diseas
approxim
mortal
rate
date
vaccin
antivir
medic
avail
prevent
clinic
treatment
mer
larg
phagedisplay
human
naiv
scfv
librari
mehta
iii
clone
danafarb
cancer
institut
use
resourc
isol
human
antibodi
merscov
anoth
project
research
group
malaysia
improv
pan
strategi
human
scfv
librari
librari
size
success
identifi
mab
specif
merscov
nucleoprotein
studi
describ
offer
insight
human
antibodi
respons
viral
pathogen
infect
provid
exampl
outbreak
scene
may
util
develop
human
antibodybas
immunotherapi
prevent
earli
treatment
viral
pathogen
fulli
human
therapeut
antibodi
current
clinic
use
discov
either
phage
display
transgen
mice
approach
phage
display
advantag
allow
research
tailor
critic
characterist
success
antibodi
drug
eg
affin
specif
crossreact
stabil
nine
phage
displayderiv
human
antibodi
current
approv
us
fda
treatment
human
diseas
tabl
demonstr
reliabl
techniqu
platform
antibodi
discoveri
adalimumab
humira
develop
basf
bioresearch
corpor
cambridg
antibodi
technolog
first
phage
displayderiv
antibodi
grant
market
approv
adalimubab
also
first
approv
fulli
human
mab
drug
adalimumab
bind
suppress
approv
treat
inflammatori
diseas
rheumatoid
psoriat
arthriti
crohn
diseas
psoriasi
adalimumab
world
bestsel
drug
sale
billion
report
abbvi
tabl
cambridg
antibodi
technolog
also
identifi
human
antibodi
target
bli
b
lymphocyt
stimul
phage
display
bli
member
tumor
necrosi
factor
superfamili
cytokin
induc
b
cell
prolifer
differenti
posit
correl
system
lupu
erythematosu
sle
antibl
antibodi
name
belimumab
market
benlysta
glaxosmithklin
becom
first
drug
approv
treatment
sle
found
cambridg
antibodi
technolog
acquir
astrazeneca
billion
tyrosin
kinas
receptor
includ
egfr
vascular
endotheli
growth
factor
receptor
play
crucial
role
tumorigenesi
higher
express
activ
tumor
normal
tissu
characterist
make
receptor
potenti
valuabl
target
drug
develop
necitumumab
portrazza
antiegfr
human
antibodi
identifi
screen
high
egfrexpress
epiderm
carcinoma
cell
nonimmun
phage
fab
librari
clone
necitumumab
approv
firstlin
therapi
combin
gemcitabin
cisplatin
treatment
squamou
nsclc
highli
express
tumor
endotheli
cell
regul
tumor
angiogenesi
also
express
surfac
cancer
cell
human
antibodi
ramucirumab
cyramza
approv
treatment
gastric
cancer
metastat
nsclc
metastat
colorect
cancer
develop
ramucirumab
initi
use
phagedisplay
human
fab
librari
dyax
contain
independ
clone
biopan
extracellular
domain
human
protein
three
fab
clone
select
base
specif
bind
nanomolar
affin
abil
neutral
vegfaactiv
signal
interestingli
three
fab
clone
crossreact
murin
share
ident
vh
sequenc
affin
matur
stringent
biopan
round
fab
clone
select
show
improv
activ
clone
subsequ
engin
human
intact
version
ramucirumab
affin
pm
cellsurfac
protein
bind
receptor
immun
cell
downregul
cell
inflammatori
activ
promot
selftoler
immun
system
mani
type
tumor
found
express
surfac
cancer
cell
use
immunesuppress
action
evad
immun
attack
avelumab
bavencio
fulli
human
lamda
antibodi
deriv
phagedisplay
fab
librari
dyax
avelumab
block
bind
also
induc
adcc
cancer
later
function
differ
immun
checkpointblock
antibodi
us
fda
approv
avelumab
treatment
urotheli
carcinoma
merkelcel
carcinoma
aggress
type
skin
cancer
psoriasi
chronic
autoimmun
inflammatori
disord
caus
skin
cell
overproduct
character
rais
inflam
red
lesion
plaqu
accompani
physic
pain
itch
guselkumab
tremfya
fulli
human
antibodi
develop
janssen
neutral
hucal
antibodi
librari
use
gener
guselkumab
licens
morphosi
guselkumab
grant
market
approv
us
fda
treatment
plaqu
psoriasi
hereditari
angioedema
rare
diseas
result
spontan
recurr
potenti
lifethreaten
attack
swell
variou
part
bodi
diseas
commonli
associ
defici
dysfunct
excess
bradykinin
product
caus
overact
plasma
kallikrein
lanadelumab
takhzyro
fulli
human
mab
deriv
dyax
phage
librari
directli
bind
activ
site
plasma
kallikrein
inhibit
bradykinin
product
lanadelumab
approv
usa
canada
prophylaxi
attack
hereditari
angioedema
patient
age
year
success
drug
develop
effort
highli
depend
obtain
patent
protect
product
technolog
avoid
infring
patent
issu
other
therefor
intellectu
properti
right
phagedisplay
antibodi
discoveri
platform
compris
chang
landscap
greatli
affect
drug
develop
current
almost
key
patent
regard
phage
display
technolog
expir
includ
mccaffertywint
patent
expir
europ
us
patent
cover
dyax
cambridg
antibodi
technolog
phage
antibodi
librari
also
reach
end
protect
period
tabl
expir
patent
allow
compani
creat
phage
display
human
antibodi
librari
advanc
march
therapeut
antibodi
clinic
lift
intellectu
properti
constraint
also
spur
academ
institut
translat
develop
phagedisplay
antibodi
clinic
mani
research
begun
take
advantag
free
technolog
exampl
wayn
maraso
colleagu
danafarb
cancer
institut
harvard
univers
construct
two
phage
display
librari
contain
billion
mehta
billion
mehta
ii
human
scfv
antibodi
phage
librari
use
identifi
numer
human
scfv
antibodi
varieti
target
jame
mark
group
also
establish
phagedisplay
human
scfv
librari
contain
billion
member
univers
california
san
francisco
librari
yield
panel
specif
antibodi
membran
protein
live
tissu
subnanomolar
affin
also
establish
phagedisplay
human
naiv
scfv
librari
institut
cellular
organism
biolog
icob
academia
sinica
taiwan
antibodi
gene
repertoir
icob
phage
antibodi
librari
isol
pbmc
healthi
human
donor
produc
librari
size
billion
individu
scfv
clone
collect
success
use
select
antibodi
bind
wide
spectrum
target
antigen
includ
pure
recombin
protein
glycan
cancer
cell
viru
particl
idea
produc
human
antibodi
transgen
mice
first
suggest
alt
et
al
propos
introduc
human
antibodi
gene
mous
germlin
idea
unpreced
provid
new
direct
develop
human
antibodi
product
et
al
clone
first
human
heavi
chain
construct
contain
two
human
vh
gene
divers
segment
link
human
heavi
chain
join
cluster
jh
constant
region
kb
construct
microinject
mililocu
plasmid
fertil
murin
egg
allow
random
insert
murin
genom
b
lymphocyt
express
human
chain
detect
level
transgen
mice
addit
hybridoma
human
igm
antibodi
could
also
establish
use
transgen
strain
taylor
et
al
clone
human
light
chain
construct
contain
one
human
kappa
light
chain
variabl
gene
human
kappa
light
chain
join
cluster
kappa
constant
region
mice
express
human
heavi
chain
human
kappa
light
chain
amount
human
antibodi
less
total
antibodi
express
human
antibodi
compat
express
mous
endogen
ig
similar
time
variou
murin
ig
knockout
mous
strain
gener
chen
et
al
knock
murin
jh
gene
gene
target
delet
inactiv
mous
ig
human
igh
igl
transgen
mice
cross
murin
igh
igl
knockout
mice
attempt
creat
line
could
gener
divers
human
antibodi
first
human
ig
transgen
mice
strain
humabmous
gener
longberg
et
al
line
human
igh
express
murin
igh
defici
mice
entir
human
igh
genom
mb
mb
human
ig
genom
introduc
mice
less
kb
sinc
antibodi
divers
come
germlin
v
j
gene
reason
introduct
human
variabl
gene
lead
divers
gener
antibodi
likewis
davi
et
al
choi
et
al
use
yeast
artifici
chromosom
yac
vector
respect
construct
human
kb
igh
kb
gene
via
yeast
homolog
recombin
green
et
al
construct
human
kb
igh
kb
genom
yac
success
introduc
mous
embryon
stem
cell
yeast
spheroplast
cell
fusion
furthermor
mendez
et
al
introduc
larger
human
kb
igh
mb
yac
mous
es
cell
cross
human
ig
mice
murin
igh
igl
knockout
mice
gener
xenomous
expect
xenomous
express
human
antibodi
rather
mous
antibodi
develop
line
elimin
interfer
mous
endogen
ig
expand
human
ig
gene
effici
human
antibodi
gener
ig
classswitch
somat
hypermut
still
remain
low
due
lack
mous
constant
region
gene
express
order
overcom
drawback
fulli
human
heavi
chain
antibodi
necessari
retain
origin
murin
constant
region
chimer
antibodi
human
fab
murin
fc
gener
mous
murin
fc
would
modul
signal
somat
hypermut
antibodi
affin
matur
effector
function
antibodi
along
line
osborn
et
al
link
human
vh
jh
gene
rat
constant
region
locu
larg
segment
human
igh
igl
subclon
link
bacteri
artifici
chromosom
bac
yac
techniqu
follow
microinject
minilocu
plasmid
fertil
rat
oocyt
meanwhil
endogen
rat
ig
loci
silenc
zinc
finger
nucleas
result
rat
strain
omnirat
chimer
human
exhibit
antibodi
product
antigen
affin
somat
mutat
similar
wildtyp
rat
lee
et
al
util
bac
creloxp
recombin
mous
es
cell
gener
mous
strain
human
vhdjh
insert
directli
upstream
murin
region
kymous
antigen
immun
kymous
process
somat
hypermut
produc
highaffin
chimer
human
antibodi
anoth
effort
murphi
et
al
use
bac
assembl
larg
human
ig
gene
serial
microinject
construct
mous
es
cell
human
igh
igl
gene
target
replac
murin
igh
igl
upstream
constant
region
velocimmun
mous
gener
human
antibodi
transgen
anim
accomplish
seven
compani
abgenix
xenomous
purchas
amgen
medarex
humabmous
purchas
bristol
myer
squibb
ligand
omnirat
kymab
kymous
regeneron
velocimmun
mous
recent
harbour
antibodi
mous
trianni
inc
trianni
mous
tabl
first
antibodi
drug
deriv
transgen
mice
approv
us
fda
transgen
animalderiv
antibodi
drug
gener
xenomous
humabmous
velocimmun
mous
market
tabl
eight
drug
use
cancer
treatment
other
autoimmun
inflammatori
diseas
seven
us
fdaapprov
antibodi
drug
gener
xenomous
tabl
first
one
panitumumab
vectibix
amgen
human
approv
treat
egfrexpress
metastat
colorect
cancer
wildtyp
kra
mab
block
interact
egfr
ligand
result
inhibit
egfr
signal
induct
cancer
cell
apoptosi
two
antibodi
drug
xenomous
use
autoimmun
dermatolog
diseas
one
secukinumab
cosentyx
novarti
human
bind
proinflammatori
cytokin
reduc
inflamm
psoriasi
brodalumab
siliq
valeant
pharmaceut
human
bind
receptor
inhibit
action
famili
cytokin
two
mab
drug
approv
us
fda
psoriasi
treatment
respect
humabmous
also
eight
antibodi
drug
approv
us
fda
tabl
two
drug
ipilimumab
yervoy
bristolmy
squibb
human
nivolumab
opdivo
bristolmy
squibb
human
use
melanoma
treatment
drug
approv
respect
ipilimumab
bind
immun
checkpoint
inhibitor
block
interact
apc
caus
cytotox
lymphocyt
kill
cancer
cell
nivolumab
recogn
reduc
inhibitori
signal
rehabilit
immun
respons
tumorspecif
cell
patient
notabl
nivolumab
also
approv
nonsmal
cell
lung
cancer
treatment
among
mab
drug
deriv
humabmous
use
autoimmun
diseas
exampl
ustekinumab
stelara
johnson
johnson
human
bind
cytokin
especi
subunit
block
proinflammatori
signal
eas
inflamm
drug
approv
sever
plaqu
psoriasi
crohn
diseas
velocimmun
mous
second
gener
transgen
chimer
mous
yield
four
approv
drug
tabl
dupilumab
dupix
sanofi
regeneron
human
bind
receptor
inhibit
pathway
eczema
treatment
sarilumab
kevzara
sanofi
regeneron
human
inhibit
signal
bind
receptor
otherwis
would
upregul
releas
rheumatoid
arthritisrel
factor
hepatocyt
two
drug
approv
notabl
despit
access
xenomous
own
cambridg
antibodi
technolog
phage
display
compani
behind
humira
astrazeneca
paid
million
breed
pair
velocimmun
mice
improv
divers
product
gener
better
antibodi
drug
major
develop
effort
yield
model
fulli
human
antibodi
mous
secondgener
chimer
human
antibodi
mice
year
sinc
first
transgen
mous
gener
continu
refin
advanc
transgen
anim
provid
ever
possibl
antibodi
drug
develop
global
pharmaceut
factori
singl
b
cell
isol
either
pbmc
lymphoid
tissu
use
micromanipul
laser
captur
microdissect
fluorescenceactiv
cell
sort
gener
mononuclear
cell
purifi
pbmc
bone
marrow
ficollpaqu
densiti
gradient
centrifug
base
b
cell
express
specif
cell
surfac
marker
differ
stage
isol
singl
b
cell
fluorescenceactiv
cell
sort
wide
util
especi
identif
rare
discret
b
cell
subpopul
antigenco
magnet
bead
fluorescenceconjug
antigen
also
often
use
select
antigenspecif
b
cell
process
known
antigen
bait
neutral
human
mab
puumala
viru
gener
b
cell
isol
use
antigenco
magnet
bead
recent
antigenconjug
fluoresc
bead
use
identifi
antigenspecif
b
cell
fluoresc
viruslik
particl
rotaviru
serv
antigen
bait
singl
rvspecif
b
cell
extract
healthi
rotavirusinfect
infant
adult
donor
hiv
envelop
protein
antigen
also
use
isol
antibodi
broadli
neutral
moreov
isol
dengu
virusspecif
memori
b
cell
report
thu
antigen
bait
may
appli
preliminari
select
tool
use
polyclon
mixtur
singl
b
cell
sort
direct
clone
ig
heavi
chain
correspond
light
chain
perform
step
involv
use
nest
seminest
revers
transcriptionpolymeras
chain
reaction
rtpcr
amplif
variabl
heavi
light
chain
identifi
b
cell
usual
forward
primer
direct
toward
igh
igl
variabl
leader
sequenc
revers
primer
complementari
ig
constant
region
optim
differ
primerset
mixtur
recoveri
vh
vl
may
improv
gene
clone
express
mammalian
cell
line
immedi
gener
recombin
mab
follow
detect
mab
reactiv
characterist
gener
mab
determin
furthermor
highthroughput
screen
evalu
secret
mab
ideal
reactiv
cellbas
microarray
chip
system
microengrav
techniqu
describ
cellbas
microarray
chip
system
immunospot
array
assay
chip
enabl
trap
secret
antibodi
chip
coat
antibodi
ig
therefor
use
identifi
recov
specif
antibodysecret
cell
microengrav
method
depend
use
soft
lithograph
techniqu
gener
microarray
compris
secret
antibodi
singl
cell
two
approach
offer
advantag
earli
rapid
identif
clone
high
affin
specif
antigen
interest
face
threat
novel
emerg
pathogen
rapid
develop
immunotherapi
insight
divers
antibodi
repertoir
benefici
singl
b
cell
sort
provid
highli
effici
technolog
achiev
goal
past
human
mab
gener
singl
b
cell
method
bacteri
parasit
viru
infect
autoimmun
diseas
among
bacteria
bacillu
anthraci
one
concern
speci
b
anthraci
fatal
pathogen
caus
sever
anthrax
diseas
human
use
biolog
weapon
although
antibiot
avail
anthrax
treatment
postexposur
prophylaxi
antianthrax
protect
antibodi
singl
human
b
cell
still
crucial
addit
treatment
toolkit
exampl
target
yeast
infect
anticandida
mab
antibodi
deriv
singl
human
b
cell
method
enhanc
phagocytosi
protect
dissemin
candidiasi
singl
b
cell
method
also
success
yield
antivir
mab
rapid
isol
dengueneutr
antibodi
human
antigenspecif
memori
bcell
cultur
character
antigenspecif
b
cell
peripher
blood
denvimmun
individu
report
anoth
exampl
iizuka
colleagu
describ
identif
cytomegaloviru
antigenspecif
human
mab
use
singl
b
cellbas
antibodi
gene
clone
rotaviru
singl
b
cell
method
perform
analyz
rotaviru
antibodi
gene
repertoir
b
cell
naiv
memori
b
cell
subset
gener
rotavirusspecif
human
mab
sort
singl
b
cell
smallintestin
mucosa
human
mab
zika
viru
also
gener
singl
b
cell
method
besid
mab
bacteri
viru
infect
singl
human
b
cell
method
also
yield
complement
factor
h
cfh
therapeut
antibodi
cancer
recombin
anticfh
antibodi
induc
complementmedi
cytotox
cdc
complement
activ
releas
anaphylatoxin
mani
virustarget
mab
also
current
clinic
trial
exampl
ebolaviru
highli
lethal
pathogen
caus
mortal
human
therapeut
mab
ebolaviru
infect
deriv
b
cell
vaccin
human
donor
survivor
impress
human
deriv
sort
memori
b
cell
target
zair
ebolaviru
glycoprotein
protect
macaqu
administ
late
day
challeng
clinic
trial
drug
phase
phase
ii
iii
acquir
immunodefici
syndrom
caus
hiv
estim
million
peopl
worldwid
infect
envelop
protein
attract
therapeut
target
antibodi
vaccin
design
five
human
mab
antihiv
envelop
protein
gener
singl
b
cell
approach
evalu
clinic
trial
phase
iii
phase
phase
iii
phase
iii
phase
phase
clinic
trial
also
conduct
prevent
sexual
transmiss
herp
simplex
viru
mb
combin
antiherp
simplex
viru
antibodi
antihiv
antibodi
differ
influenza
virus
caus
epidem
ever
year
influenza
vaccin
use
measur
prevent
season
influenza
singl
b
cell
isol
gener
potent
broadli
neutral
antiinfluenza
antibodi
becom
popular
undertak
human
mab
target
hemagglutinin
stalk
influenza
viru
clone
singl
human
plasmablast
cell
influenza
viru
vaccin
donor
phase
ii
clinic
trial
monotherapi
acut
uncompl
season
influenza
otherwis
healthi
adult
recent
complet
ct
contain
two
human
mab
ct
ct
creat
celltrion
phase
ii
rg
also
name
gener
genentech
modifi
version
singl
b
cell
isol
method
current
examin
phase
trial
phase
ii
trial
anoth
antibodi
tcn
stop
profil
respiratori
syncyti
viru
rsv
antibodi
repertoir
memori
b
cell
natur
infect
adult
gener
neutral
antibodi
rsvinfect
infant
undertaken
well
antirsv
antibodi
develop
medimmun
current
evalu
safeti
efficaci
phase
ii
clinic
trial
past
decad
gener
mab
singl
b
cell
technolog
becom
increasingli
attract
howev
still
us
fdaapprov
therapeut
mab
develop
method
use
clinic
treatment
diseas
although
singl
b
cell
technolog
possess
sever
irreplac
advantag
still
challeng
overcom
exampl
antigen
label
techniqu
configur
sort
antigen
eg
monom
dimer
design
primer
set
import
consider
success
gener
mab
futur
recoveri
mab
singl
b
cell
platform
may
power
tool
combin
next
gener
sequenc
develop
novel
diagnost
pharmacokinet
applic
clinic
therapeut
phage
display
yeast
display
wide
use
affin
matur
antibodi
due
amen
easili
screen
high
affin
variant
high
throughput
applic
method
increas
antibodi
affin
broadli
divid
two
broad
categori
first
gener
larg
randomli
mutat
librari
cdr
entir
variabl
domain
sequenc
follow
select
higher
affin
variant
larg
number
mutant
anoth
approach
prepar
small
librari
focus
mutagenesi
hotspot
mutagenesi
mimic
vivo
affin
matur
focus
method
high
affin
variant
select
random
individu
posit
six
cdr
discret
point
variabl
domain
call
hotspot
usual
practic
combin
differ
mutat
result
small
increas
affin
combin
differ
mutat
may
addit
synergist
effect
result
substanti
increas
affin
antibodi
antigen
phage
display
technolog
employ
identifi
high
affin
antibodi
antibodi
gene
mutat
librari
stringent
biopan
condit
includ
decreas
antigen
amount
extend
incub
intens
wash
step
competit
solubl
antigen
use
phage
display
vh
vl
mutat
librari
affin
antibodi
improv
diversif
antibodi
gene
initi
step
affin
matur
vitro
step
may
achiev
use
variou
strategi
random
mutat
target
mutat
chain
shuffl
mutat
randomli
introduc
variabl
region
antibodi
gene
errorpron
pcr
mutat
e
coli
strain
chain
shuffl
approach
one
two
chain
vh
vl
fix
recombin
repertoir
partner
chain
produc
nextgener
librari
moreov
mutat
introduc
particular
region
antibodi
gene
type
target
mutat
approach
employ
diversifi
cdr
residu
shown
effect
amelior
affin
antibodi
therefor
method
relev
vivo
somat
mutat
b
cell
evolut
mutat
accumul
effici
cdr
framework
residu
field
therapeut
antibodi
undergon
rapid
growth
recent
year
becom
domin
forc
therapeut
market
howev
still
signific
growth
potenti
therapeut
antibodi
field
tradit
antibodi
use
treatment
cancer
autoimmun
diseas
infecti
diseas
molecular
mechan
specif
diseas
clearli
elucid
specif
protein
molecul
involv
pathogenesi
identifi
antibodi
may
provid
effect
therapeut
option
exampl
anticgrp
receptor
antibodi
erenumab
galcanezumab
fremanezumab
develop
prevent
migrain
antiproprotein
convertas
subtilisinkexin
type
antibodi
evolocumab
alirocumab
use
treatment
hypercholesterolemia
antifibroblast
growth
factor
antibodi
burosumab
use
treat
xlink
hypophosphatemia
antibodi
sarilumab
tocilizumab
use
treatment
rheumatoid
arthriti
antifactor
ixaxa
antibodi
emicizumab
valuabl
treatment
hemophilia
antivon
willebrand
factor
antibodi
caplacizumab
approv
treatment
thrombot
thrombocytopen
purpura
antibodi
approv
new
indic
near
futur
therapeut
antibodi
roughli
separ
two
broad
categori
fig
first
categori
nake
antibodi
directli
use
diseas
therapi
cancer
treatment
categori
may
act
sever
differ
mechan
includ
mediat
pathway
eg
adcccdc
direct
target
cancer
cell
induc
apoptosi
target
tumor
microenviron
target
immun
checkpoint
mediat
pathway
antibodi
kill
cancer
cell
recruit
natur
killer
cell
immun
cell
recent
new
technolog
develop
made
enhanc
therapeut
effect
adcc
cdc
antibodi
fc
point
mutat
modif
glycosyl
improv
cancer
cell
kill
capabl
direct
induct
apoptosi
cancer
cell
tradit
prefer
mechan
therapeut
antibodi
regard
target
tumor
microenviron
antibodi
inhibit
tumorigenesi
target
factor
involv
cancer
cell
growth
exampl
avastin
target
vascular
endotheli
growth
factor
vegf
inhibit
blood
vessel
growth
around
tumor
shut
suppli
nutrient
requir
cancer
cell
growth
immun
checkpoint
proven
valuabl
target
cancer
treatment
futur
studi
evalu
synergist
effect
antibodi
chemotherapeut
drug
radiotherapi
biolog
agent
greatli
benefit
develop
antibodi
therapeut
furthermor
identif
novel
biomark
may
improv
efficaci
specif
antibodybas
therapi
human
diseas
second
categori
antibodi
drug
addit
modif
made
antibodi
order
enhanc
therapeut
valu
gener
approach
includ
immunocytokin
antibodydrug
conjug
antibodyradionuclid
conjug
bispecif
antibodi
immunoliposom
chimer
antigen
receptor
cell
cart
therapi
creat
immunocytokin
select
cytokin
fuse
antibodi
enhanc
deliveri
specif
antibodi
drug
conjug
consist
antibodi
target
cancerspecif
marker
conjug
small
molecul
drug
antibodi
enhanc
deliveri
tumor
site
increas
efficaci
small
molecul
reduc
side
effect
reduc
nonspecif
toxic
nontarget
tissu
antibodi
may
also
conjug
radionuclid
order
direct
radiotherapi
specif
tumor
site
bispecif
antibodi
antibodi
target
two
receptor
engin
enhanc
therapeut
effect
antibodyengag
effector
cell
function
may
enhanc
therapeut
efficaci
bispecif
antibodi
regard
immunoliposom
bind
site
antibodi
scfv
fab
cleav
constant
region
subsequ
conjug
differ
nanodrug
deliveri
system
liposom
drug
provid
specif
target
lastli
cart
involv
insert
gene
chimer
cell
receptorantibodi
target
specif
cancer
marker
cell
engin
cell
target
kill
cancer
cell
recent
year
approach
garner
major
attent
scientif
medic
commun
due
signific
clinic
benefit
cancer
patient
mani
case
patient
experienc
complet
remiss
even
complet
cure
cancer
although
new
method
wellestablish
gener
fulli
human
antibodi
human
antibodi
transgen
mice
human
singl
b
cell
antibodi
techniqu
phage
display
still
advantag
antibodi
drug
discoveri
platform
base
effici
econom
vitro
select
methodolog
recent
advanc
techniqu
appli
antibodi
discoveri
includ
highthroughput
robot
screen
next
gener
sequenc
singl
cell
sequenc
techniqu
expect
greatli
acceler
identif
specif
phage
binder
facilit
mab
develop
use
research
clinic
diagnost
pharmaceut
treatment
human
diseas
review
current
approv
mab
one
may
easili
see
sophist
format
develop
respons
challeng
pose
therapeut
indic
mab
engin
solut
highlight
antibodydrug
conjug
glycoengin
mab
immunomodul
bispecif
mab
cart
cell
summar
five
technic
platform
relat
product
therapeut
antibodi
includ
chimer
antibodi
human
phage
display
transgen
mice
singl
b
cell
antibodi
technolog
fig
phage
display
transgen
mice
singl
b
cell
antibodi
technolog
proven
reliabl
method
gener
human
antibodi
enorm
storehous
antibodi
encod
gene
unknown
properti
high
qualiti
antibodi
divers
phage
antibodi
librari
critic
success
identif
therapeut
mab
addit
optim
select
phage
display
librari
depend
target
antigen
qualiti
antigen
immobil
tight
control
bind
wash
condit
furthermor
care
prescreen
design
condit
tailor
characterist
antibodi
discov
biopan
includ
conform
specif
epitop
specif
intern
neutral
interspeci
crossreact
current
nine
fulli
human
antibodi
discov
phage
librari
approv
therapi
dozen
phagederiv
antibodi
therapeut
clinic
trial
wait
enter
market
tabl
order
improv
qualiti
antibodi
drug
research
develop
sever
transgen
anim
includ
fulli
human
mice
secondgener
human
chimer
mous
continu
refin
advanc
transgen
anim
provid
option
antibodi
drug
develop
global
pharmaceut
factori
transgenicderiv
mab
approv
therapeut
use
come
three
compani
abgenix
xenomous
medarex
humabmous
regeneron
velocimmun
depend
immun
protocol
high
affin
human
antibodi
obtain
select
clone
gener
anim
select
mainli
accomplish
hybridoma
technolog
current
approv
human
mab
discov
three
transgen
anim
tabl
past
decad
gener
mab
isol
singl
b
cell
becom
increasingli
attract
approach
date
us
fdaapprov
therapeut
mab
deriv
method
howev
possess
sever
major
advantag
ongo
challeng
current
solv
success
method
reli
heavili
antigen
label
techniqu
configur
sort
antigen
eg
monom
dimer
set
primer
use
amplif
futur
recoveri
mab
singl
b
cell
expect
becom
power
tool
combin
next
gener
sequenc
diagnost
pharmacokinet
applic
clinic
therapeut
result
highli
activ
develop
antibodi
drug
recent
decad
mab
emerg
among
major
class
therapeut
agent
treatment
mani
human
diseas
especi
cancer
immunolog
infecti
neural
metabol
diseas
sale
growth
regulatori
approv
mab
product
slow
late
first
chimer
mab
approv
annual
sale
billion
subsequ
approv
human
fulli
human
mab
rate
product
approv
sale
mab
product
increas
rapidli
global
sale
revenu
mab
product
billion
fig
continu
growth
mab
product
come
year
expect
major
driver
overal
biopharmaceut
product
sale
